Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : BofA Securities
Deal Size : $175.0 million
Deal Type : Public Offering
Mineralys Prices $175M Underwritten Public Offering of Common Stock
Details : The net proceeds from the offering will be used to fund the clinical development of MT-4129 (lorundrostat). It is being evaluated for the treatment of Uncontrolled or Resistant Hypertension.
Product Name : MT-4129
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : BofA Securities
Deal Size : $175.0 million
Deal Type : Public Offering
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : BofA Securities
Deal Size : $287.5 million
Deal Type : Public Offering
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Details : The net proceeds from the offering will be used to fund the clinical development of MT-4129 (lorundrostat). It is being evaluated for the treatment of Uncontrolled or Resistant Hypertension.
Product Name : MT-4129
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2025
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : BofA Securities
Deal Size : $287.5 million
Deal Type : Public Offering
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mineralys Reports Positive Lorundrostat Data in Uncontrolled Hypertension
Details : MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension or resistant hypertension.
Product Name : MT-4129
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mineralys Completes Enrollment in Explore-CKD Phase 2 Lorundrostat Trial
Details : MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension or resistant hypertension.
Product Name : MT-4129
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mineralys Announces Phase 2 Trial of Lorundrostat for Sleep Apnea and Hypertension
Details : MLS-101 (lorundrostat) is an oral highly selective aldosterone synthase inhibitor. It is being evaluated for the treatment of obstructive sleep apnea in patients with hypertension.
Product Name : MLS-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mineralys Completes Launch-HTN Trial Enrollment for Lorundrostat in Hypertension
Details : MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension or resistant hypertension.
Product Name : MT-4129
Product Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2024
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Mineralys Completes Target Enrollment in Lorundrostat Trial For Hypertension
Details : MLS-101 (lorundrostat) is a orally administered, highly selective aldosterone synthase inhibitor. It is being evaluated in phase 3 clinical trials for the treatment of uncontrolled hypertension.
Product Name : MLS-101
Product Type : Small molecule
Upfront Cash : Not Applicable
September 25, 2024
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : TCGX
Deal Size : $120.0 million
Deal Type : Private Placement
Mineralys Therapeutics Announces $120 Million Private Placement Financing
Details : The company intends to use the net proceeds for the development of MLS-101 (lorundrostat) for the treatment of uncontrolled and resistant hypertension.
Product Name : MLS-101
Product Type : Small molecule
Upfront Cash : Undisclosed
February 08, 2024
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : TCGX
Deal Size : $120.0 million
Deal Type : Private Placement
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. It is being evaluated in phase 3 clinical trials for the treatment of uncontrolled and resistant hypertension.
Product Name : MLS-101
Product Type : Small molecule
Upfront Cash : Not Applicable
December 21, 2023
Lead Product(s) : Lorundrostat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lorundrostat
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MLS-101 (lorundrostat) is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension and chronic kidney disease.
Product Name : MLS-101
Product Type : Small molecule
Upfront Cash : Not Applicable
July 17, 2023
Lead Product(s) : Lorundrostat
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable